Setara Biosciences launched with $90 million in funding and a lead program designed to address two indications: Charcot-Marie-Tooth disease type 2C and overactive bladder. The company’s small-molecule candidate targets the rare neuromuscular disorder while also aiming at the more prevalent bladder condition, reflecting an effort to build a platform with clinical reach across distinct patient populations. The lead asset was sourced from Actio Biosciences, which Jazz Pharmaceuticals acquired recently. Setara’s structure ties its early-stage clinical development to that acquired chemistry, positioning the new entrant to move quickly into clinic while leveraging pedigree from prior development work. For investors, the raise signals continued appetite for first-in-class or differentiated small-molecule approaches in neuromuscular and urology-adjacent spaces, particularly when a program carries both rare disease relevance and broader commercial potential.